On October 24, 2023 Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, reported two poster presentations: one on the company’s lead mRNA therapeutic candidate, NTX-250, which targets human papillomavirus (HPV)-driven cancers; the other on its latest therapeutic candidate, NTX-471, which targets CD47 and CCR4 (Press release, Nutcracker Therapeutics, OCT 24, 2023, View Source [SID1234636319]). These data will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC’s) 38th Annual Meeting & Pre-Conference Programs (SITC 2023) in San Diego, CA, from November 1 through 5, 2023.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Nutcracker’s presentation on NTX-250 will describe how its three RNA-encoded protein components (HPV E6/E7, IL-12, and LIGHT) work together to drive enhanced immune responses and tumor clearance in murine models of HPV-driven tumors, while also providing immunogenic memory. The presentation on NTX-471 will describe unique mRNA compositions that can selectively target CD47 on cancerous cells over those on red blood cells, potentially alleviating the anemic side effects seen with anti-CD47 drugs currently under development.
Poster Presentations at SITC (Free SITC Whitepaper) 2023
Title: mNTX-250, a novel multimodal HPV-16 mRNA-based therapeutic, induces potent anti-tumor responses and establishes HPV-16 specific immune memory
Abstract Number: 134
Session Date and Time: Saturday, Nov 4th, 2023 9:00 AM – 7:00 PM
Lead Author: Ou Li
Title: NTX-471, engineered multivalent SIRPa and bispecific SIRPa-antiCCR4 molecules demonstrate superior activity providing path for mRNA-expressed in vivo biologics
Abstract Number: 1359
Session Date and Time: Friday, November 3, 2023: 9:00 AM – 7:00 PM
Lead Author: Gunasekaran Kannan
Poster presentations will be accessible in person and virtually. All accepted abstracts will be available in a Journal for ImmunoTherapy of Cancer (JITC) supplement, which will be published on October 31 at 9:00 a.m. EST. For more information about SITC (Free SITC Whitepaper) 2023, please visit View Source